Backgrounds: The restenosis rate after stenting is high in small vessel lesions. With the advent of drug-eluting stent (DES) technology, interest and enthusiasm has been generated in stenting small coronary vessels. Recent studies such as SIRIUS trial and TAXUS IV trial have demonstrated that drug eluting stents significantly reduced angiographic restenosis rate in small vessels (<2.8mm). But, until now, datas concerning procedural feasibility or outcome of both DES have not been evaluated in Korea. Therefore, in this study, we compare the outcomes of Sirolimus-eluting stents (Cypher짰) vs. Paclitaxel-eluting stents (Taxus짰) in patients with small vessel lesions Methods: Retrospective analysis was done on 485 lesions in 451 consecutive patients in the COMATE DES registry. The reference diameter of all analyzed lesion was less than 2.8mm and stent diameter was less than 2.8mm also. Angiographic follow up data was available for 151 lesions (31.4%). Results: Cypher짰 stents were implanted in 329 lesions and Taxus짰 stents in 156 lesions (reference vessel diameter of 2.51짹0.35mm vs. 2.49짹0.40mm, lesion length of 23.42짹11.9mm vs. 21.02짹11.7). The percent diameter stenosis decreased from 79.0짹15 to 5.3짹11 and 78.8짹14 to 6.0짹12 (p=0.88), and acute gain was 1.91짹0.45mm and 1.86짹0.54mm (p=0.25) respectively. Angiographic follow up data after 6 months was available for 151 lesions. The follow up MLD was 2.20짹0.54mm vs 1.97짹0.73mm (p=0.028), late loss was 0.25짹0.53 vs. 0.42짹0.71 (p=0.097), and the follow up percent diameter stenosis was 12.5짹20 vs. 22.7짹28 (p=0.011) respectively. Including sudden death, myocardial infarction, subacute thrombosis, total 5 (3.1%) MACE were seen at Cypher짰 group and 5 (5.7%) at Taxus짰 group, but there was no statistical significance. Conclusions: Among two groups, the procedural success rate was high without significant difference. Although no difference in 12 months MACE and event free survival was seen, follow up angiographic data showed slightly higher MLD and lower percent diameter stenosis in Cypher stent group. Further investigations should be followed in future.